Supporting the NHS to close the diagnostic gap in gynaecological health.
Supporting the NHS to close the diagnostic gap in gynaecological health.
Advancing evidence, enabling safe adoption and building long-term, sustainable partnerships.
1 in 3
Eligible women in the UK are not screened within the recommended timeframe
85%
Of UK women want a choice between self-sampling and clinic-based screening
70%
Prefer self-sampling at home over attending a clinic
Our work focuses on three core areas:
Supporting healthcare systems & commercial partners to adopt innovation safely
Building strategic partnerships that enable responsible, scalable growth
Generating rigorous clinical and real-world evidence
Our NHS partners
Our NHS partners
Working with health innovation networks across England to bring Daye's at-home diagnostics into clinical pathways.
Operation Model
A complimentary sampling option to fit the existing pathway
A complimentary sampling option to fit the existing pathway
No change to downstream clinical management (e.g. cytology).
1. Supporting the NHS to eradicate cervical cancer by 2040
We run structured ICB & PCN pilots, generate real-world evidence on uptake and clinical outcomes, and deliver the health economic case for adoption - modelled cost savings, uplift in screening uptake and reduced clinical resource burden.
1. Supporting the NHS to eradicate cervical cancer by 2040
We run structured ICB & PCN pilots, generate real-world evidence on uptake and clinical outcomes, and deliver the health economic case for adoption - modelled cost savings, uplift in screening uptake and reduced clinical resource burden.
1. Supporting the NHS to eradicate cervical cancer by 2040
We run structured ICB & PCN pilots, generate real-world evidence on uptake and clinical outcomes, and deliver the health economic case for adoption - modelled cost savings, uplift in screening uptake and reduced clinical resource burden.
2. Ongoing refinement to cervical screening uptake
We align with NSC, NICE and RCOG frameworks, integrate with existing cytology recall and colposcopy pathways, and meet NHS clinical governance standards. We are on the SBS framework and are endorsed by the NHS Innovation Accelerator.
2. Ongoing refinement to cervical screening uptake
We align with NSC, NICE and RCOG frameworks, integrate with existing cytology recall and colposcopy pathways, and meet NHS clinical governance standards. We are on the SBS framework and are endorsed by the NHS Innovation Accelerator.
2. Ongoing refinement to cervical screening uptake
We align with NSC, NICE and RCOG frameworks, integrate with existing cytology recall and colposcopy pathways, and meet NHS clinical governance standards. We are on the SBS framework and are endorsed by the NHS Innovation Accelerator.
3. Providing critical screening intelligence
We map screening coverage at ICB and PCN level, quantify the 1-in-3 unscreened gap against the NHS 80% target, and identify under-served cohorts where self-sampling has the greatest impact. We surface the data commissioners need to make the case for cost-effective, improved pathways.
3. Providing critical screening intelligence
We map screening coverage at ICB and PCN level, quantify the 1-in-3 unscreened gap against the NHS 80% target, and identify under-served cohorts where self-sampling has the greatest impact. We surface the data commissioners need to make the case for cost-effective, improved pathways.
3. Providing critical screening intelligence
We map screening coverage at ICB and PCN level, quantify the 1-in-3 unscreened gap against the NHS 80% target, and identify under-served cohorts where self-sampling has the greatest impact. We surface the data commissioners need to make the case for cost-effective, improved pathways.
“Health Innovation East has been excited to support innovation that has the potential to fundamentally improve access and engagement in women’s health services. Daye’s Diagnostic Tampon is a powerful example of patient-centred design - combining clinically robust HPV diagnostics with a familiar, less invasive format that could help overcome some of the biggest barriers to cervical screening participation across underserved communities.”
Joanna Dempsey
Principle Advisor
“Health Innovation East has been excited to support innovation that has the potential to fundamentally improve access and engagement in women’s health services. Daye’s Diagnostic Tampon is a powerful example of patient-centred design - combining clinically robust HPV diagnostics with a familiar, less invasive format that could help overcome some of the biggest barriers to cervical screening participation across underserved communities.”
Joanna Dempsey
Principle Advisor
“Health Innovation East has been excited to support innovation that has the potential to fundamentally improve access and engagement in women’s health services. Daye’s Diagnostic Tampon is a powerful example of patient-centred design - combining clinically robust HPV diagnostics with a familiar, less invasive format that could help overcome some of the biggest barriers to cervical screening participation across underserved communities.”
Joanna Dempsey
Principle Advisor
Daye Diagnostic Tampon is free from petroleum-derived plastics and carbon-neutral - helping the NHS deliver on its Net Zero commitment.
Daye Diagnostic Tampon is free from petroleum-derived plastics and carbon-neutral - helping the NHS deliver on its Net Zero commitment.
The Diagnostic Tampon was selected as the NHS Rewired Pitchfest 2026 winner.
Operated by Anne's Day Ltd, a company registered in England and Wales (Co. No. 11044785) 4th Floor 22 Southwark Bridge Road, London, United Kingdom, SE1 9HF. Anne's Day Ltd is a wholly-owned subsidiary of Daye Biotech Ltd (Ireland, Co. No. 788588), Pavilion House, 31 Fitzwilliam Square, Dublin 2, D02 F403.
The Daye Diagnostic Tampon is a UKCA- and CE-marked medical device, manufactured under ISO 13485 and GMP, for self-collection of vaginal samples analysed by UKAS-accredited (ISO 15189) partner laboratories. Daye services are not intended to diagnose, treat, cure, or prevent disease in isolation; HPV, STI, and hormone results require interpretation by a qualified healthcare professional. Information on this site is educational and not a substitute for medical advice. This site is directed at users in the United Kingdom. Products, services, indications, regulatory status, and clinical claims described here apply to the UK only and may differ in other jurisdictions.
© 2026 Daye Limited, 4th Floor, 22 Southwark Bridge Road, London SE1 9HF, UK
Operated by Anne's Day Ltd, a company registered in England and Wales (Co. No. 11044785) 4th Floor 22 Southwark Bridge Road, London, United Kingdom, SE1 9HF. Anne's Day Ltd is a wholly-owned subsidiary of Daye Biotech Ltd (Ireland, Co. No. 788588), Pavilion House, 31 Fitzwilliam Square, Dublin 2, D02 F403.
The Daye Diagnostic Tampon is a UKCA- and CE-marked medical device, manufactured under ISO 13485 and GMP, for self-collection of vaginal samples analysed by UKAS-accredited (ISO 15189) partner laboratories. Daye services are not intended to diagnose, treat, cure, or prevent disease in isolation; HPV, STI, and hormone results require interpretation by a qualified healthcare professional. Information on this site is educational and not a substitute for medical advice. This site is directed at users in the United Kingdom. Products, services, indications, regulatory status, and clinical claims described here apply to the UK only and may differ in other jurisdictions.
Operated by Anne's Day Ltd, a company registered in England and Wales (Co. No. 11044785) 4th Floor 22 Southwark Bridge Road, London, United Kingdom, SE1 9HF. Anne's Day Ltd is a wholly-owned subsidiary of Daye Biotech Ltd (Ireland, Co. No. 788588), Pavilion House, 31 Fitzwilliam Square, Dublin 2, D02 F403.
The Daye Diagnostic Tampon is a UKCA- and CE-marked medical device, manufactured under ISO 13485 and GMP, for self-collection of vaginal samples analysed by UKAS-accredited (ISO 15189) partner laboratories. Daye services are not intended to diagnose, treat, cure, or prevent disease in isolation; HPV, STI, and hormone results require interpretation by a qualified healthcare professional. Information on this site is educational and not a substitute for medical advice. This site is directed at users in the United Kingdom. Products, services, indications, regulatory status, and clinical claims described here apply to the UK only and may differ in other jurisdictions.
Our work focuses on three core areas:
Prioritise patient comfort
Supporting healthcare systems & commercial partners to adopt innovation safely
Building strategic partnerships that enable responsible, scalable growth
Our work focuses on three core areas:
Generating rigorous clinical and real-world evidence
Supporting healthcare systems & commercial partners to adopt innovation safely
Building strategic partnerships that enable responsible, scalable growth